Project: A novel targeted antibody treatment against BK virus-induced kidney graft rejection

Acronym BKVab (Reference Number: 113381)
Duration 01/10/2019 - 03/10/2022
Project Topic This consortium aims to develop a therapeutic monoclonal antibody (mAb) as novel treatment to prevent BKV induced nephropathy and graft loss in kidney transplant recipients (KTRs). This project will deliver the therapeutic antibody with an associated efficacy and safety data package. The data package will be used to negotiate a license deal with a pharmaceutical company.
Network Eurostars 2
Call Eurostars Cut–off 11

Project partner

Number Name Role Country
1 Memo Therapeutics AG Coordinator Switzerland
2 OcellO B.V. Partner Netherlands
3 Laboratory of Pharmacology and Toxicology (LPT) GmbH & Co. KG Partner Germany